

# Development and evaluation of a training intervention for cancer teams talking about randomised trials

<b>Submission date</b> 31/03/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/03/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 24/01/2022	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-study-looking-at-peoples-attitudes-towards-clinical-trials-and-how-doctors-and-nurses-give-information-about-taking-part-in-a-trial>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Valerie Jenkins

### Contact details

Brighton and Sussex Medical School  
University of Sussex, Biology Building  
Falmer  
Brighton  
United Kingdom  
BN1 9QG

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

4205

# Study information

## Scientific Title

A multicentre randomised controlled trial to improve communication with patients about clinical trials within cancer teams

## Acronym

Teams Talking Trials

## Study objectives

The study is a randomised trial to examine whether the communication with patients about clinical trials can be improved within cancer teams. The aims of the study are to:

1. Examine the attitudes of multidisciplinary team (MDT) members to clinical trials and the influence these have on trial recruitment
2. Examine the attitudes of patients towards clinical trials, and their satisfaction with and comprehension of information received about trials and conduct and evaluate specific training for cancer teams about trial discussions.

Team members who undergo focused training will:

1. Display greater confidence about trial discussions post course
2. Be clearer about the informational roles played by colleagues when discussing trials

Patients seen by teams who undergo training will:

1. Rate clarity of information provided more highly
2. Provide more positive reasons for accepting or declining trial end

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

South East Wales Research Ethics Committee Panel C on 16/02/2007 (ref: 07/WSEO3/17)

## Study design

Randomised interventional multicentre process of care trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Diagnostic

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Topic: National Cancer Research Network; Subtopic: All Cancers/Misc Sites; Disease: All

**Interventions**

The intervention is a 1.5 training course in communication about randomised clinical trials for cancer teams. Each team will receive the intervention either following 6 or 12 months of data collection.

Follow Up Length: 0 month(s)

Study Entry : Other

Details:

Patients attending clinics and hospitals for treatment or follow up are recruited to survey A. 50 patients for each team will be recruited into the survey A.

The number of patients for survey B will vary according to each team, and the number will be recorded pre- and post-educational intervention.

Each patient completes a survey and is noted on the accrual spreadsheet as registered, although the protocol design is randomised.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Numbers of patients approached about trials, analysed in Jan 2011

**Secondary outcome measures**

Attitudes and involvement of team members, analysed in June 2010

**Overall study start date**

04/06/2007

**Completion date**

30/12/2010

**Eligibility****Key inclusion criteria**

1. Cancer teams working in Wales
2. Patients who have had a randomised clinical trial discussed with them by one of the team members
3. Either sex, aged 18 - 90 years

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 1600; UK Sample Size: 1600

**Key exclusion criteria**

Cancer teams in other parts of the UK

**Date of first enrolment**

04/06/2007

**Date of final enrolment**

30/12/2010

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

Brighton and Sussex Medical School

Brighton

United Kingdom

BN1 9QG

**Sponsor information****Organisation**

Brighton and Sussex Medical School (UK)

**Sponsor details**

University of Sussex

Biology Building

Falmer

Brighton

England

United Kingdom

BN1 9QG

-

Scott.Harfield@bsuh.nhs.uk

**Sponsor type**

University/education

**Website**

<http://www.bsuh.nhs.uk>

**ROR**

<https://ror.org/01qz7fr76>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK (CRUK) (UK)

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

Not provided at time of registration

**IPD sharing plan summary**

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2013		Yes	No
<a href="#">Plain English results</a>			24/01/2022	No	Yes